كندا - الإنجليزية - Health Canada

takeda canada inc - alogliptin (alogliptin benzoate); pioglitazone (pioglitazone hydrochloride) - tablet - 12.5mg; 30mg - alogliptin (alogliptin benzoate) 12.5mg; pioglitazone (pioglitazone hydrochloride) 30mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

كندا - الإنجليزية - Health Canada

takeda canada inc - alogliptin (alogliptin benzoate); pioglitazone (pioglitazone hydrochloride) - tablet - 12.5mg; 45mg - alogliptin (alogliptin benzoate) 12.5mg; pioglitazone (pioglitazone hydrochloride) 45mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

كندا - الإنجليزية - Health Canada

takeda canada inc - alogliptin (alogliptin benzoate); pioglitazone (pioglitazone hydrochloride) - tablet - 25mg; 15mg - alogliptin (alogliptin benzoate) 25mg; pioglitazone (pioglitazone hydrochloride) 15mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

كندا - الإنجليزية - Health Canada

takeda canada inc - alogliptin (alogliptin benzoate); pioglitazone (pioglitazone hydrochloride) - tablet - 25mg; 30mg - alogliptin (alogliptin benzoate) 25mg; pioglitazone (pioglitazone hydrochloride) 30mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

كندا - الإنجليزية - Health Canada

takeda canada inc - alogliptin (alogliptin benzoate); pioglitazone (pioglitazone hydrochloride) - tablet - 25mg; 45mg - alogliptin (alogliptin benzoate) 25mg; pioglitazone (pioglitazone hydrochloride) 45mg - dipeptidyl peptidase-4 (dpp-4) inhibitors

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

eurocept international b. v. - sodium phenylbutyrate - carbamoyl-phosphate synthase i deficiency disease - various alimentary tract and metabolism products - treatment of chronic management of urea-cycle disorders.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

orpharma nz limited - sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules;  ;   - oral granules - 483 mg - active: sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules     excipient: ethylcellulose hypromellose macrogol 1500 povidone sugar spheres - pheburane is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. pheburane should be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, and protein-free calorie supplements). pheburane is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. geriatrics (> 65 years of age): pheburane has not been studied in the geriatric population.

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

galderma (uk) ltd - amorolfine hydrochloride - medicated nail lacquer - 5 %w/v - amorolfine

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

galderma international - amorolfine - medicated nail lacquer - 5 percent weight/volume - other antifungals for topical use; amorolfine